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OBJECTIVE—Diabetic and prediabtic states, including insulin resistance, fasting hypergly-
cemia, and hyperinsulinemia, are associated with metabolic dysregulation. These components
have beenindividuallylinked to increased risksof cognitive decline and Alzheimer’sdisease.We
aimed to comprehensively relate all of the components of metabolic dysregulation to cognitive
function and brain magnetic resonance imaging (MRI) in middle-aged adults.
RESEARCH DESIGN AND METHODS—Framingham Offspring participants who un-
derwent volumetric MRI and detailed cognitive testing and were free of clinical stroke and de-
mentia during examination 7 (1998–2001) constituted our study sample (n = 2,439; 1,311
women; age 61 6 9 years). We related diabetes, homeostasis model assessment of insulin re-
sistance(HOMA-IR),fastinginsulin,andglycohemoglobinlevelstocross-sectionalMRImeasures
of total cerebral brain volume (TCBV) and hippocampal volume and to verbal and visuospatial
memory and executive function. We serially adjusted for age, sex, and education alone (model
A), additionally for other vascular risk factors (model B), and ﬁnally, with the inclusion of
apolipoprotein E-´4, plasma homocysteine, C-reactive protein, and interleukin-6 (model C).
RESULTS—We observed an inverse association between all indices of metabolic dysfunction and
TCBVinallmodels(P,0.030).TheobserveddifferenceinTCBVbetweenparticipantswithandwithout
diabetes was equivalent to approximately 6 years of chronologic aging. Diabetes and elevated glycohe-
moglobin, HOMA-IR, and fasting insulin were related to poorer executive function scores (P , 0.038),
whereas only HOMA-IR and fasting insulin were inversely related to visuospatial memory (P , 0.007).
CONCLUSIONS—Metabolic dysregulation, especially insulin resistance, was associated
with lower brain volumes and executive function in a large, relatively healthy, middle-aged,
community-based cohort.
Diabetes Care 34:1766–1770, 2011
A
lzheimer’s disease (AD) afﬂicts as
many as 50% of people aged .85
years and is associated with signiﬁ-
cant health care and societal costs. With
the rapid aging of the U.S. population, it is
expected that, by the year 2050, the preva-
lence of AD will increase from the currently
estimated 5 million to .11 million afﬂicted
persons aged .65 years, unless effective
prevention or treatment is found (1).
Because late-onset AD is a slowly pro-
gressive disease that affects people aged
.65 years, some have argued that merely
delaying its onset by several years would
signiﬁcantly decrease individual risk
and the population burden of disease.
The Framingham study estimated that a
5-year delay in the onset of AD would be
equivalent to a reduction of lifetime risk by
h alf ,fr om1 4to7%( 2) .T h us ,alth ou g hvar -
ious disease-modifying agents are being
investigated, a parallel search for modiﬁ-
ableriskfactorsthatcoulddelaytheonset
of AD would be a worthwhile endeavor.
Diabetes is a potentially modiﬁable
risk factor that has been related in several
population-based studies of older indi-
viduals to the risk of incident dementia
and AD (3). However, the argument that
it represents a causal factor would be
strengthened if similar associations were
demonstrablerelatingtheentirespectrum
of prediabetic and diabetic states with
subclinical measures of subsequent AD
risk in younger persons aged ,65 years
wh oar e ,a sye t ,fr e eofcl in ic a ldi s ea s e.Fu r-
thermore, examining insulin resistance
(IR), hyperinsulinemia, and hyperglyce-
mia, the three interwoven components of
the diabetic and prediabetic states, could
help clarify the relative importance of
these elements in determining the risk
of AD. To examine the possible associa-
tion of midlife diabetic and prediabetic
states with cognitive and brain magnetic
resonance imaging (MRI) markers of
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ORIGINAL ARTICLEsubsequent dementia and AD, we related
diabetes, glycohemoglobin A1c (HbA1c),
fasting serum insulin levels, and IR in the
middle-aged, cognitively intact Framingham
Offspring study population to measures
of structural and functional brain aging.
RESEARCH DESIGN AND
METHODS
Study population
The Framingham study’s original cohort
has been evaluated biennially since 1948
and screened prospectively for incident
dementia since 1978. A sample drawn
from the offspring (and spouses of the
offspring) of the original participants
(Framingham Offspring cohort) was en-
rolled in 1970–1972 and has been exam-
ined eight times during the past 37 years,
approximately once every 4 years. Partic-
ipants who attended offspring examina-
tion 7 (between 1998 and 2001) were
invited to participate in brain MRI studies
and a neuropsychologic assessment. The
study population comprised 2,439 indi-
viduals (1,311 women), with a mean age
of 62 6 9 years who agreed to participate
and were also free of clinical stroke, de-
mentia, or other neurologic conditions
such as a brain tumor that could alter
MRI and cognitive performance.
Brain MRI study
Image acquisition. The methods fol-
lowed for brain MRI have been described
previously(4).Inbrief,subjectsunderwent
neuroimaging on a Siemens Magnetom
(Munich, Germany) 1-T or 1.5-T ﬁeld
strength machine using a double spin-
echo coronal imaging sequence of 4-mm
contiguous slices from nasion to occiput.
Imaging data were transferred to a central
location for processing and analyzed by
operators who were blinded to the sub-
ject’s identity, age, sex, exposure to stroke
risk factors,and cognitive performance on
neuropsychologic testing. Previously re-
ported semiautomated analyses of pixel
distributions based on mathematic mod-
eling of MRI pixel intensity histograms for
cerebrospinal ﬂuid and white and gray
brain matter were used to determine the
optimalthresholdofpixelintensitytobest
distinguish cerebrospinal ﬂuid from brain
matter (5). All analyses were performed
using QUANTA 6.2, a custom-designed
image analysis package, operating on an
Ultra 5 workstation (Sun Microsystems,
Santa Clara, CA).
Assessment of brain MRI measures. MRI
measures assessed consisted of total
cerebral brain volume (TCBV), hippocam-
pal volume (HV), and white matter hyper-
intensity volume. Brain volume was
determinedbymanualoutliningincoronal
images of the intracranial vault above the
tentorium to determine the total cranial
volume as a measure of head size. Once the
skull and other nonbrain tissues were re-
moved from the image, mathematic mod-
eling was performed to determine total
parenchymal brain volume above the
tentorium (cerebral). HV was estimated
using operator-deﬁned, manually traced
boundaries. Because the medial wall of the
temporal horn consists of the hippocam-
pus, atrophy of the hippocampus will re-
sult in enlargement of the temporal horn
volume. White matter hyperintensity vol-
ume was measured according to previ-
ously published methods (6), expressed
asaproportionofthetotalintracranialvol-
ume,and log-transformed tonormalize its
distribution. We estimated the equiva-
lency between the mean change in TCBV
associatedwithchronologicagingandthat
associated with the presence of diabetes by
dividing the regression coefﬁcient fordiabe-
tes by the regression coefﬁcient for age (7).
Cognitive evaluation
A comprehensive, well standardized, neu-
ropsychologic test battery was adminis-
tered to all participants and has been
described previously (8). The neuropsy-
chologic evaluation consisted of a 40-min
test battery that included tests of verbal
memory and abstract reasoning that were
previously associated with an increased
risk of developing AD in the original co-
hort (9). Also included were tests of
frontal executive function that are sensi-
tiveindetectingcognitiveimpairmentin
p e r s o n sw i t hd i a b e t e s( 1 0 ) .T h ec o g n i -
tivedomainsthatwestudiedwereverbal
memory (Wechsler Memory Scale–Logical
Memory), visual memory (Wechsler Mem-
ory Scale–Visual Reproduction), and exec-
utive function (Trail Making Tests A & B).
The MRI and neuropsychologic testing
were performed on the same day for most
participants and, in all cases, by evaluators
whowereblindtothediabetes,HbA1c,fast-
ing insulin, and IR data.
Diabetic and prediabetic states
Fasting glucose, HbA1c,a n df a s t i n gi n s u -
lin levels were estimated from blood sam-
plesdrawnattheOffspringexamination7
after participants had fasted overnight for
at least 8 h. Diabetes was determined by
use of insulin or other diabetes medica-
tion or a fasting glucose concentration
$126 mg/dL. Fasting glucose concentra-
tions were measured in fresh specimens
with a hexokinase reagent kit (A-gent
Glucose Test; Abbott Laboratories, Inc.,
South Pasadena, CA); the intra-assay co-
efﬁcient of variation (CV) was ,3%.
HbA1c was measured using high-
performance liquid chromatography
(HPLC) assays standardized to Diabetes
Control and Complications Trial values by
theNationalGlycohemoglobinStandardiza-
tion Program (11). The HbA1c assays have
intra- and interassay CVs ,3%. Assay drift
in the HPLC method used in Framingham
Offspring Study is prevented by the use of
long-term stored reference samples.
Plasma insulin concentrations were
measured using the Coat-A-Count
125I–
labeled radioimmunoassay (Diagnostic
Products, Los Angeles, CA); this assay
has a cross-reactivity with proinsulin at
themidcurveof40%;theintra-andinter-
assay CVs were 5 to 10%.
IRwasestimatedusingastandardized
measureofinsulinsensitivity:thehomeo-
stasis model assessment of IR (HOMA-IR).
The HOMA-IR (mmol/L 3 mU/mL) for-
mula is deﬁned as fasting insulin (mU/mL)
times fasting glucose (mmol/L)/22.5.
Statistical analyses
We related presence or absence of di-
abetesandlevelsofHbA1c,fastinginsulin,
and HOMA-IR to the MRI and cognitive
outcomes listed in RESEARCH DESIGN AND
METHODS. Data for participants receiving
insulin treatment were excluded in the
analysesinvolvinginsulinlevels.Wecon-
structed linear regression models ad-
justed for covariates previously shown to
affect brain volume and cognitive function
in the Framingham cohort including:
c M o d e lA :a g e ,s e x ,e d u c a t i o n( f o rc o g -
nitive measures) only;
c Model B: the above with inclusion of
nondiabetes cardiovascular risk factors
at examination 7: systolic blood pres-
sure, smoking, prevalent cardiovascu-
lar disease;
c Model C: additional adjustment for
factors previously associated with risk
of dementia in the Framingham origi-
nal cohort, namely, apolipoprotein E
(apoE)-´4 genotype, and serum homo-
cysteinelevels,C-reactiveprotein(CRP),
and interleukin-6 (IL-6) at examina-
tion 7.
We also adjusted for the time interval
between examination 7 and MRI or cog-
nitive testing in all analyses.
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Tan and AssociatesIn secondary analyses, we excluded
subjects with clinical diabetes and
looked at the effect of the duration of
diabetes on the relationship between
diabetesandMRImeasuresbystratifying
the subjects into three categories: 1)
nondiabetic as determined at Offspring
examination 7 and at the earlier exami-
nation 5 (1991–1995) using the same
criteria described earlier (referent); 2)
nondiabetic at examination 5 and dia-
betic at examination 7; 3)d i a b e t i ca te x -
aminations 5 and 7.
RESULTS—The characteristics of the
study population at examination 7 (1998–
2001) are presented in Table 1. We ob-
served an inverse association between all
indices (diabetes, HbA1c, HOMA-IR, fast-
ing insulin level) of metabolic dysfunction
evaluated at examination 7 and TCBV in
allmodels (Table 2). Adjustmentfor cova-
riates (models B and C; Table 2) did not
appreciably alter these associations. The
observed difference in TCBV of 1.24%
between participants with and without
diabetes was equivalent to the effect of
approximately 6 years of chronologic
aging. Of note, the association of IR and
hyperinsulinemia with TCBV remained
signiﬁcant when the analysis was re-
stricted to subjects who had not yet de-
veloped clinical diabetes (Table 3). In
contrast, none of the metabolic indices
were associated with HV.
Considering the cognitive measures,
wefoundthatexamination7diabetesand
HbA1c, HOMA-IR and fasting insulin
were each related to poorer executive
function. This inverse relationship be-
tween executive function and HbA1c,
HOMA-IR, and fasting insulin persisted
even after adjustment for covariates (Ta-
b l e2 )a n dt h ee x c l u s i o no fp a r t i c i p a n t s
with clinical diabetes from the analysis
(Table 3). HOMA-IR and fasting insulin,
but not clinical diabetes or HbA1c,w e r e
inversely related to visuospatial memory
(Table 2). These associations remained
signiﬁcant after adjustment for covariates
(models B and C; Table 2).
A surprising ﬁnding was an apparent
association between diabetes and better
performance in verbal memory tasks, al-
though this effect was attenuated after
adjustment for all covariates. There was
an interaction with insulin levels, so that
this apparent beneﬁcial effect was only
seen in subjects who also had elevated
plasma insulin levels and was not seen in
the subsample of participants who were
not receiving insulin.
Stratifying participants according to
theirdiabetesstatus at examinationcycles
5 and 7 revealed that the cross-sectional
association between diabetes and TCBV
was present only in those participants who
had diabetes at both examination cycles
(diabetes duration $4y e a r s ;P , 0.001)
and not in those who developed diabetes
onlyatexamination7(P=0.113).Nosuch
differential patterns according to length of
time with clinical diabetes were observed
for the other indices of metabolic dysfunc-
tion and measures of brain aging (Supple-
mentary Table 1A).
CONCLUSIONS—Inthemiddle-aged
communitysampleofstroke-anddementia-
free Framingham Offspring participants,
we observed that clinical diabetes and
various metabolic indices associated with
diabetic and prediabetic states were asso-
ciated with the subclinical changes of
smaller brain volumes and poorer cogni-
tive performance, especially on tests of
executive function and visual memory.
These ﬁndings were observed even among
participants who did not have clinical di-
abetes, and the most consistent association
was with IR, which is important in the
evolution of clinical type 2 diabetes.
The relationship between diabetes
and cognition was reported .85 years
ago, when Miles and Root (12) observed
that patients with diabetes did not per-
formaswellascontrolsubjectsintestsof
m e m o r y ,m e n t a la r i t h m e t i c ,a n dp s y -
chomotor efﬁciency. Multiple studies
since then have shown an adverse effect
of baseline diabetes status on concomi-
tantcognitivefunctionandcognitivede-
cline on follow-up. Diabetes has been
associated with cognitive changes that
affect learning and memory, mental
speed, and mental ﬂexibility (13), and
population-based studies have also re-
lated diabetes to the risk of incident de-
mentia and AD (3). The Memory in
Diabetes (MIND) substudy of the Action
toControlCardiovascularRiskinDiabe-
tes (ACCORD) trial showed an inverse
relationship between glycohemoglobin
levels and performance on cognitive tests;
whereas,fastingplasmaglucose,ameasure
with greater day-to-day variability, was
not associated with test performance (14).
The cognitive impairment associated with
diabetesmaybeginevenbeforetheappear-
ance of clinical disease; compared with
women with normal glucose, women
with impaired fasting glucose levels had
worse baseline cognitive scores and an al-
most twofold risk of developing cognitive
impairment over a 4-year period (15).
The pathophysiologic mechanisms
underlying the purported relationship
betweendiabetes,prediabetes,anddemen-
tia, thus far, remains unclear but could in-
volve direct effects on AD neuropathology
or indirectly via diabetic vasculopathy,
leading to cerebrovascular brain injury.
Hyperglycemia can be harmful by pro-
moting oxidative stress, the formation of
toxic advanced glycation end products,
and induction for receptors for advanced
glycation end products. A direct effect of
insulin on cognition is supported by ob-
servations that insulin readily crosses the
Table 1—Characteristics of subjects at examination cycle 7 (1998–2001)
Characteristic Women Men
n 1,311 1,128
Age (years) 61 6 96 1 6 9
High-school degree 97.3 95.5
Current cigarette smoking 12.8 11.9
Systolic blood pressure 125 6 20 127 6 17
ApoE4 22.8 22.6
Plasma homocysteine (mmol/L) 7.7 6 2.5 9.1 6 4.1
CRP (mg/L) 4.5 6 5.4 3.7 6 6.8
IL-6 (pg/mL) 3.8 6 4.5 4.0 6 5.8
Diabetes 7.2 13.3
Fasting glucose (mg/dL) 99 6 22 108 6 29
HbA1c (%) 5.6 6 0.8 5.7 6 1.1
HOMA-IR (mmol/L 3 mU/mL) 3.9 6 3.7 5.0 6 4.2
Fasting insulin (mU/mL) 15.6 6 12.5 18.7 6 14.2
Time interval (years)
Examination 7 to MRI 0.8 6 0.8 0.8 6 0.9
Examination 7 to cognitive test 0.8 6 0.9 0.8 6 0.9
Continuous data are presented as mean 6 SD; categoric data as percentages.
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Metabolic dysregulation and brain volumeblood-brain barrier and the high concen-
tration of insulin receptors on the hippo-
campus and medial temporal cortex (16),
areas of the brain that are primarily in-
volved in memory and affected by AD
neuropathology. At excessively high or
low levels, insulin has been shown in
vitro to downregulate choline acetyl-
transferase(17), theenzymethatcatalyzes
the production of the neurotransmitter
acetylcholine, which is deﬁcient in AD.
Furthermore,insulinhasbeenimplicated
in t phosphorylation and amyloid depo-
sition, the pathophysiologic mechanisms
for AD (18).
Diabetes is an established risk factor
for stroke and other vascular disorders,
leading toan alternate hypothesisthat the
link between diabetes and dementia is
indirect, mediated by vascular pathology
(19). In the Rotterdam Study, however,
diabeteswasassociatedwithMRImarkers
of AD risk, including smaller hippocam-
pus and amygdala volumes, even after ac-
counting for vascular pathology (20).
We found that, in this late adult
population with a mean age of 62 years,
clinicaldiabetesandeachofthemetabolic
dysfunction markers of IR, hyperinsu-
linemia, and hyperglycemia (elevated
HbA1c) were associated with signs of
accelerated brain aging, as measured by
MRI TCBV, and by poorer performance
on tests of executive function. The asso-
ciation with IR and hyperinsulinemia,
whichareearlymarkersofacompensated
prediabetic state, were also observed in a
subsample without clinical diabetes.
In addition, we found that there ap-
pear to be different patterns of associa-
tion between markers of a hyperglycemic
s t a t ev e r s u sm e a s u r e so fI Rw h e ne a c hi s
related to cognitive markers of aging.
Measures of IR (HOMA-IR and fasting
insulin levels) were inversely associated
with visual memory and executive func-
tion, whereas glycemic indices (diabetes
and HbA1c) were inversely associated only
with performance on executive function.
We also found a marginally signiﬁcant
direct association between diabetes and
verbal memory, which disappeared after
adjusting for all covariates. This ﬁnding
is contrary to previously published studies
and may be a chance artifact given our co-
hort’s younger average age compared with
previous studies. Because it was restricted
to persons on insulin supplementation, it
could reﬂect a beneﬁcial effect of exoge-
nous insulin on memory (21).
Our data strengthen earlier ﬁndings
relating diabetes status to cognitive
function, even in stroke- and dementia-
free community-dwelling middle-aged
men and women. Taken together, these
ﬁndingssuggestthattheinsulinresistant
states seen in prediabetes and diabetes,
as well as hyperglycemia, accelerate brain
structural and cognitive aging, albeit in
slightly different patterns, with the most
robust associations being with IR.
In contrast to investigations into the
association between glycemia and cog-
nition, fewer studies have explored the
possible links between insulin levels and
Table 2—Association between metabolic dysregulation measures and markers of brain aging
Variable Model
HOMA-IR
(mmol/L 3 mU/mL) P
Fasting insulin
(mU/mL) P HbA1c (%) P Diabetes P
TCBV A 20.07 6 0.02 <0.001 20.02 6 0.01 <0.001 20.31 6 0.07 <0.001 21.24 6 0.20 <0.001
B 20.06 6 0.02 <0.001 20.02 6 0.01 <0.001 20.27 6 0.07 <0.001 21.08 6 0.20 <0.001
C 20.04 6 0.02 0.003 20.01 6 0.01 0.050 20.23 6 0.07 0.002 20.97 6 0.21 <0.001
HV A 20.000 6 0.000 0.428 20.000 6 0.000 0.731 20.001 6 0.001 0.476 20.003 6 0.004 0.380
B 20.000 6 0.000 0.461 20.000 6 0.000 0.746 20.001 6 0.001 0.510 20.003 6 0.004 0.436
C 20.000 6 0.000 0.521 20.000 6 0.000 0.891 20.001 6 0.001 0.423 20.003 6 0.004 0.522
Verbal memory A 0.007 6 0.006 0.287 0.001 6 0.002 0.781 0.02 6 0.02 0.406 0.15 6 0.07 0.031
B0 . 0 0 7 6 0.006 0.295 0.001 6 0.002 0.744 0.02 6 0.02 0.515 0.14 6 0.07 0.039
C0 . 0 0 5 6 0.007 0.503 20.000 6 0.002 0.808 0.02 6 0.02 0.495 0.14 6 0.07 0.059
Visual memory A 20.02 6 0.01 0.003 20.005 6 0.002 0.005 20.04 6 0.02 0.114 20.10 6 0.07 0.169
B 20.02 6 0.01 0.004 20.005 6 0.002 0.007 20.03 6 0.02 0.274 20.08 6 0.07 0.280
C 20.02 6 0.01 0.003 20.005 6 0.002 0.006 20.02 6 0.02 0.385 20.08 6 0.07 0.262
Executive function A 20.03 6 0.01 <0.001 20.007 6 0.002 <0.001 20.07 6 0.02 0.002 20.15 6 0.07 0.031
B 20.03 6 0.01 <0.001 20.007 6 0.002 <0.001 20.06 6 0.02 0.009 20.13 6 0.07 0.064
C 20.03 6 0.01 <0.001 20.007 6 0.002 <0.001 20.06 6 0.02 0.022 20.15 6 0.07 0.038
Model A: Adjusted for age, sex, education. Model B: Adjusted for age, sex, education, systolic blood pressure, smoking, history of cardiovascular disease. Model C:
Adjusted for age, sex, education, systolic blood pressure, smoking, history of cardiovascular disease, apoE-´4 genotype, serum homocysteine levels, CRP, IL-6.
Statistically signiﬁcant relationships are in boldface.
Table 3—Association between metabolic dysregulation measures and markers of brain aging after exclusion of participants
with clinical diabetes*
Variable
HOMA-IR
(mmol/L 3 mU/mL) P
Fasting insulin
(mU/mL) P
HbA1c
(%) P
TCBV 20.10 6 0.03 ,0.001 20.03 6 0.01 ,0.001 0.02 6 0.12 0.859
HV 0.000 6 0.001 0.784 0.000 6 0.000 0.543 0.000 6 0.002 0.999
Verbal memory 0.008 6 0.009 0.405 0.001 6 0.002 0.574 20.035 6 0.043 0.404
Visual memory 20.011 6 0.009 0.193 20.004 6 0.002 0.132 0.000 6 0.043 1.000
Executive function 20.026 6 0.009 0.003 20.007 6 0.002 0.002 20.102 6 0.042 0.016
Values in boldface type are signiﬁcant. *Adjusted for age, sex, and education (for cognitive measures).
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Tan and AssociatesIR, and brain structure and cognitive per-
formance. Although hyperinsulinemia
has been directly linked (22) to AD risk,
there is also accumulating evidence link-
ing insulin levels and cognitive perfor-
mance in individuals without dementia.
Hyperinsulinemia has been associated
with lower scores on the Mini-Mental
State Examination in individuals without
dementia (23). Furthermore, IR, as mea-
suredbytheHOMA-IR,haslikewisebeen
associated with poorer cognition and,
more recently, with diffusely decreased
cortical glucose uptake on ﬂuorodeoxy-
glucose-positron emission tomography
scans (24,25). Our ﬁndings of inverse re-
lationships between fasting insulin levels,
HOMA-IR, and brain volume and cogni-
tive performance—even after controlling
f o rv a s c u l a rr i s kf a c t o r s — appear to sup-
port these ﬁndings.
One limitation of our study is that we
only examined a cross-sectional associa-
tion but did not examine the association
of these measures with change. Another
limitation is the primarily white ethnicity
of the Framingham study sample; hence,
these associations need to be examined
among community-dwelling individuals of
other ethnicities. Our results do support
ongoing studies to examine whether early
detection and management of diabetes
and metabolic dysfunction, particularly IR,
would be able to delay the clinical onset of
cognitive disorders.
Diabetic and prediabetic states charac-
terized byIR,hyperinsulinemia, andhyper-
glycemia, when present in late middle age,
are related to decreased brain volume and
lower cognitive performance on executive
function and memory tasks. These results
extend the body of evidence linking meta-
bolic dysfunction to the risk of dementia
andADinlatelife.Theseresultssuggestthat
clinical trials attempting to delay cognitive
and structural brain loss by controlling
metabolic dysfunction, even in individuals
free of clinical diabetes and as early as the
7th decade, might be warranted.
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